Abstract:Abstract Background: Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC) is clinically and biologically heterogeneous. CDK4/6 inhibitors (CDK4/6i) are proven to be effective in different molecular subtypes of HR+/HER2- BC, including the PAM50 luminal B. However, not all patients benefit to the same extent and new biomarkers for response are needed. The aim of this study was to develop a computational workflow to predict the response of patients with luminal B BC to treatment with CDK4/6i in combination with endocrine therapy (ET). Methods: The main part of the workflow is a computational model representing the mechanisms of action of the drugs and their influence on protein signaling and cell proliferation in the tumor. The model was trained on publicly available data from BC cell lines (Western blot time courses and viability dose-response data). The model was then used to predict response in patients by incorporating gene expression profiles obtained at baseline. The output of the model was a score indicating how strongly the tumor responded to the treatment. Gene expression data determined using the nCounter BC360 panel was available at baseline from two patient cohorts: 1) the CORALLEEN phase II trial which evaluated neoadjuvant ribociclib plus letrozole vs multi-agent chemotherapy in postmenopausal patients with luminal B by PAM50, HR+/HER2- early BC (Prat et al. Lancet Oncology. 2020), 2) a retrospective study of postmenopausal patients with HR+/HER2-/Luminal B advanced BC treated with CDK4/6i plus ET in the first line setting at Hospital Clinic Barcelona (hereafter CDK cohort). PAM50 risk of relapse (ROR) and Ki67 levels were considered as outcome for the CORALLEEN patients. Progression free survival (PFS) was available in the CDK cohort. Area under the ROC Curve (AUC) was used to estimate the discrimination performance of the model. Differences were tested for statistical significance using Wilcoxon rank-sum test. Hazard ratios were estimated using Cox regression to investigate the association with PFS. Results: The computational model used here describes the dynamics of relevant protein-protein and drug-protein interactions to the treatment of CDK4/6i plus ET. The model showed high agreement with the training data obtained from cell lines (Pearson correlation of 0.88 and 0.95). The ability of the trained model to predict treatment outcome in patients was validated in baseline samples of the CDK4/6i arm (n=51) and the chemotherapy arm (n=52) of the CORALLEEN trial, and baseline Luminal B primary tumors of the CDK cohort (n=19). For each patient, a response score was calculated by the model using the expression of 6 genes at baseline as input. This response score was significantly associated with patient response in both cohorts. The model identified patients with high Ki67 (AUC of 0.80 (95% CI 0.64 - 0.92)) and high ROR (AUC of 0.78 (95% CI 0.64 - 0.89)) after treatment in the CDK4/6i arm of the CORALLEEN cohort and was used to stratify patients into different response groups. The AUC in the chemotherapy arm of CORALLEEN for identifying high Ki67 was 0.44 (95% CI 0.29 - 0.58), indicating that the predictions are specific to CDK4/6i plus ET treatment. Additionally, stratification of patients in the CDK cohort into either two or three groups based on the response score was linked to PFS (HR=3.71 (95% CI 0.97 - 14.16), p=0.055 and HR=2.92 (95% CI 1.08 - 7.86), p=0.034, respectively). Conclusion: A mechanistic model was developed, trained on cell line data, and then used to predict treatment outcome of patients with HR+/HER2-/PAM50 Luminal B BC treated with CDK4/6i plus ET. This approach showed significant association with observed outcome and could be used to assign patients to different response groups, indicating the usefulness of the model as a potential marker for response. Citation Format: Leonard Schmiester, Fara Brasó-Maristany, Vessela Kristensen, Arnoldo Frigessi, Aleix Prat, Alvaro Köhn-Luque. A computational model of the mechanisms of action of combined endocrine therapy and CDK4/6 inhibition predicts outcome in patients with Luminal B breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO4-14-09.

Abstract 1959: BLU-222, a potent and highly selective CDK2 inhibitor, demonstrates antitumor activity as monotherapy and as combination treatment in CCNE1- aberrant endometrial cancer models

Abstract 4622: Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models

Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer

Abstract OT2-16-04: KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer: A single arm, multicenter, phase 2 study

Abstract 1143: Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers

Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2- breast cancer and CCNE1high ovarian cancer

Abstract CT117: Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2- advanced breast cancer (ABC)

Abstract 5642: Discovery of SCR-8079, a Novel and Selective CDK2/4/6 Inhibitor Overcomes the Resistance to CDK4/6 Inhibition and Demonstrates Broad Anti-Tumor Activities in Breast Cancers

Abstract 3309: Discovery of potent and selective bivalent CDK2 degraders that demonstrate activity in CCNE1amp driven tumors

Abstract 4649: BLX-3030, a potent, selective, orally available small molecule CDK9 inhibitor for aggressive variant prostate cancers

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Abstract 1057: Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models

Abstract 5957: Development of a selective, oral ATP-competitive CDK9 inhibitor, BLX-3030, for treatment of pancreatic cancer

Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor

Abstract 599: Combination of CDK4/6 inhibitors with biguanides for treatment of triple negative breast cancer

Abstract 4610: Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

Abstract 5722: Preclinical activity of CDK4/6 inhibitor alone or in sequential combination with chemotherapy using breast cancer cell line-derived organoid culture

Abstract PO4-14-09: A computational model of the mechanisms of action of combined endocrine therapy and CDK4/6 inhibition predicts outcome in patients with Luminal B breast cancer

Abstract 5990: Druggable CRISPR/Cas9 screen identifies Cyclin E1 (CCNE1) as a key mediator of sensitivity to CDK4/6 inhibition in non-small cell lung cancer (NSCLC)

Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models

Abstract PS16-22: Targeting Resistance to Current CDK4/6 Therapies by RGT-419B, an Inhibitor with Optimized Kinase Activity Spectrum